2025
Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study
Janetzki J, Kim J, Minty E, Lee J, Morales D, Khera R, Kim C, Alshammari T, DuVall S, Matheny M, Falconer T, Kim S, Phan T, Nguyen P, Hsu M, Hsu J, Park R, Man K, Seager S, Van Zandt M, Gilbert J, Ryan P, Schuemie M, Suchard M, Hripcsak G, Pratt N, You S. Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study. EClinicalMedicine 2025, 81: 103096. PMID: 39975698, PMCID: PMC11836508, DOI: 10.1016/j.eclinm.2025.103096.Peer-Reviewed Original ResearchUrinary tract infectionRisk of aortic aneurysmTreat urinary tract infectionsOutpatient settingAortic aneurysmIndex dateCohort studyHazard ratioUrinary tract infection treatmentYonsei University College of MedicineRetrospective cohort studyPropensity scoreCox proportional hazards modelsPropensity-matched pairsRandom-effects meta-analysisProportional hazards modelNational Health and Medical Research Council (NHMRCUniversity College of MedicineSystemic fluoroquinolonesTract infectionsNo significant differenceBayesian random-effects meta-analysisFollow-upPrimary outcomeIncreased risk
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2021
A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST)
Oikonomou EK, Van Dijk D, Parise H, Suchard MA, de Lemos J, Antoniades C, Velazquez EJ, Miller EJ, Khera R. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). European Heart Journal 2021, 42: 2536-2548. PMID: 33881513, PMCID: PMC8488385, DOI: 10.1093/eurheartj/ehab223.Peer-Reviewed Original ResearchConceptsStable chest painChest painPrimary endpointMajor adverse cardiovascular eventsNon-fatal myocardial infarctionAdverse cardiovascular eventsStudy's primary endpointCoronary artery diseaseClinical trial populationsCox regression modelParticipant-level dataSCOT-HEARTCardiovascular eventsCause mortalityHazard ratioPatients 5Artery diseaseFunctional testingPROMISE trialTrial populationMyocardial infarctionLower incidenceStudy populationPainCollected variables
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply